Synopsis: GlaxoSmithKline has voluntarily paused activities in its Phase III GRACE trial on an experimental…
Tag:
Adverse
-
-
Ropeginterferon
FDA Approves Ropeginterferon Alfa-2b-njft (Besremi) Treatment for Rare Blood Disease Polycythemia Vera (PV).
by adminSUMMARY: PharmaEssentia Corporation a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven…
-
Gsk
GlaxoSmithKline’s Novel Anemia (Daprodustat) has Notched up A First-In-Class Success While AstraZeneca-FibroGen’s Akebia Failed.
by adminSYNOPSIS: GlaxoSmithKline Plc released positive trial results for a potential blockbuster anemia pill the company…